Abstract: Objective The aim of this study was to investigate the efficacy of ezetimibe (EZM) and polyene phosphatidylcholine (PPC) combination in the treatment of patients with non-alcoholic steatohepatitis (NASH). Methods 94 patients with NASH were admitted to our hospital between February 2021 and February 2024, and were randomly divided into observation group (n=47) andcontrol group (n=47), receiving EZM and PPCcombination treatment or PPC treatment alone for six months.Serum adiponectin (APN) and resistin levels were assayed by ELISA. Liver stiffness measurement(LSM) and controlled attenuation parameter(CAP) were detected by Fibroscan. Results By end of six month observation, serum ALTand AST levels in the observation group were (42.3±5.9)U/L and (45.1±5.5)U/L, both significantly lower than [(58.2±6.0)U/L and (59.3±5.2)U/L, respectively, P<0.05] in the control; serum TC, TG and fasting blood glucoselevels were (4.8±0.4)mmo/L, (2.1±0.4)mmo/Land (5.8±1.2)mmo/L, all significantly lower than [(5.8±0.8)mmo/L, (3.4±0.6)mmo/L and (6.4±1.5)mmo/L, respectively, P<0.05] in the control; serum APN level was (15.6±2.8)mg/mL, much higher than [(10.8±2.0)mg/mL, P<0.05], while serum resistin level was (5.2±0.6)mg/mL, much lower than [(7.2±0.9)mg/mL, P<0.05] in the control, and the CAP was (252.5±26.3)dB/m, also much lower than [(286.3±30.6)dB/m, P<0.05]in the control group. Conclusion Combination of EZM and PPCin treatment of patients with NASH could effectively ameliorate liver function tests, and promote glucose and lipid metabolism, which might be related to regulation of adipokines.

Key words: Non-alcoholic steatohepatitis, Ezetimibe, Polyene phosphatidylcholine, Therapy